Biogen Inc.

BIIBleader

Biogen is a pioneer in neuroscience therapeutics, leading in multiple sclerosis treatments and advancing Alzheimer's disease therapy with Leqembi alongside a profitable biosimilars business.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($9.8B)

Data statis (memuat keuangan langsung…)

Multiple Sclerosis (38%)

Biosimilars (28%)

Rare Disease (18%)

Alzheimer's & Other (16%)

Komposisi segmen dan pelanggan utama

Detail produk

Leqembi (lecanemab)15%

Anti-amyloid antibody for early Alzheimer's disease (co-developed with Eisai)

Multiple Sclerosis Portfolio40%

Tecfidera, Vumerity, Tysabri, and Avonex for MS

Rare Disease (SMA)15%

Spinraza (nusinersen) for spinal muscular atrophy

Biosimilars30%

Biosimilar versions of TNF inhibitors and oncology drugs

Hubungan Rantai Pasok

Pesaing

Regeneron Pharmaceuticals

Neuroscience pipeline

Dampak: Low — limited direct overlap

Eli Lilly and Company

Alzheimer's disease treatments

Dampak: High — Lilly's donanemab vs Leqembi

Viatris Inc.

Biosimilar market

Dampak: Medium — both in biosimilars

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Biogen Inc..

Info Perusahaan

Kantor Pusat

Cambridge, Massachusetts, USA

Didirikan

1978

Karyawan

7,500+

Situs Web

biogen.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor